Gilead's rheumatoid arthritis pill approved in Japan

Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted it a licence following an FDA rejection in August.

Analysts question Gilead's commitment to arthritis drug afte...

The FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage male fertility, prompting speculation that the big US pharma could be

Gilead and Galapagos shares hit as filgotinib disappoints

Gilead and Galapagos' late-stage trial of their ulcerative colitis drug filgotinib has hit its target – but shares in both companies were down after data suggested the drug may struggle for

Lilly, Galapagos suspend trials as COVID-19 hits health syst...

Novartis’ $100m bet on eczema drug fails as MOR106 developme...

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).

Gilead says arthritis drug filgotinib fails in follow-up use...